Serum CGRP in migraine patients using erenumab as preventive treatment
Aim Serum levels of Calcitonin Gene-Related Peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients before and after starting treatment with erenumab were measured to evaluate the association with clinical treatment response. Methods Blood samples were collected from the cubital fossa be...
Saved in:
| Published in: | Journal of headache and pain Vol. 23; no. 1; pp. 120 - 7 |
|---|---|
| Main Authors: | , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Milan
Springer Milan
01.12.2022
Springer Nature B.V BMC |
| Subjects: | |
| ISSN: | 1129-2369, 1129-2377, 1129-2377 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Aim
Serum levels of Calcitonin Gene-Related Peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients before and after starting treatment with erenumab were measured to evaluate the association with clinical treatment response.
Methods
Blood samples were collected from the cubital fossa before (T0) and 2–4 weeks after (T1) starting treatment with erenumab. Clinical response was monitored using a daily headache e-diary. Serum levels of CGRP-LI, assessed using radioimmunoassay, were compared between T0 and T1, correcting for migraine reduction. In addition, for both T0 and T1, linear regression models were constructed using migraine reduction as outcome and serum CGRP-LI as independent variable, corrected for age, gender and monthly migraine days (MMD) at baseline.
Results
Serum CGRP-LI did not differ between T0 and T1 (
p
= 0.30). However, there was an interaction between time and reduction in MMD (
p
= 0.01). Absolute reduction in MMD in the third month after treatment with erenumab was associated with serum CGRP-LI at T1, 2–4 weeks after starting treatment with erenumab (
p
= 0.003), but not with serum CGRP-LI at T0 (
p
= 0.24).
Conclusion
Lower serum CGRP-LI 2–4 weeks after starting treatment with erenumab was associated with a higher reduction in migraine days after three months of treatment. Although the underlying mechanisms remain to be determined, this suggests that changes in CGRP levels, shortly after starting erenumab, are important for its clinical effect.
Highlights
• Lower serum levels of calcitonin gene-related peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients at 2–4 weeks after starting treatment with erenumab were associated with better treatment response after three months.
• Early changes in serum CGRP may be important for the clinical effect of erenumab in migraine. |
|---|---|
| AbstractList | • Lower serum levels of calcitonin gene-related peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients at 2–4 weeks after starting treatment with erenumab were associated with better treatment response after three months. • Early changes in serum CGRP may be important for the clinical effect of erenumab in migraine. Serum levels of Calcitonin Gene-Related Peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients before and after starting treatment with erenumab were measured to evaluate the association with clinical treatment response.AIMSerum levels of Calcitonin Gene-Related Peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients before and after starting treatment with erenumab were measured to evaluate the association with clinical treatment response.Blood samples were collected from the cubital fossa before (T0) and 2-4 weeks after (T1) starting treatment with erenumab. Clinical response was monitored using a daily headache e-diary. Serum levels of CGRP-LI, assessed using radioimmunoassay, were compared between T0 and T1, correcting for migraine reduction. In addition, for both T0 and T1, linear regression models were constructed using migraine reduction as outcome and serum CGRP-LI as independent variable, corrected for age, gender and monthly migraine days (MMD) at baseline.METHODSBlood samples were collected from the cubital fossa before (T0) and 2-4 weeks after (T1) starting treatment with erenumab. Clinical response was monitored using a daily headache e-diary. Serum levels of CGRP-LI, assessed using radioimmunoassay, were compared between T0 and T1, correcting for migraine reduction. In addition, for both T0 and T1, linear regression models were constructed using migraine reduction as outcome and serum CGRP-LI as independent variable, corrected for age, gender and monthly migraine days (MMD) at baseline.Serum CGRP-LI did not differ between T0 and T1 (p = 0.30). However, there was an interaction between time and reduction in MMD (p = 0.01). Absolute reduction in MMD in the third month after treatment with erenumab was associated with serum CGRP-LI at T1, 2-4 weeks after starting treatment with erenumab (p = 0.003), but not with serum CGRP-LI at T0 (p = 0.24).RESULTSSerum CGRP-LI did not differ between T0 and T1 (p = 0.30). However, there was an interaction between time and reduction in MMD (p = 0.01). Absolute reduction in MMD in the third month after treatment with erenumab was associated with serum CGRP-LI at T1, 2-4 weeks after starting treatment with erenumab (p = 0.003), but not with serum CGRP-LI at T0 (p = 0.24).Lower serum CGRP-LI 2-4 weeks after starting treatment with erenumab was associated with a higher reduction in migraine days after three months of treatment. Although the underlying mechanisms remain to be determined, this suggests that changes in CGRP levels, shortly after starting erenumab, are important for its clinical effect.CONCLUSIONLower serum CGRP-LI 2-4 weeks after starting treatment with erenumab was associated with a higher reduction in migraine days after three months of treatment. Although the underlying mechanisms remain to be determined, this suggests that changes in CGRP levels, shortly after starting erenumab, are important for its clinical effect. AimSerum levels of Calcitonin Gene-Related Peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients before and after starting treatment with erenumab were measured to evaluate the association with clinical treatment response.MethodsBlood samples were collected from the cubital fossa before (T0) and 2–4 weeks after (T1) starting treatment with erenumab. Clinical response was monitored using a daily headache e-diary. Serum levels of CGRP-LI, assessed using radioimmunoassay, were compared between T0 and T1, correcting for migraine reduction. In addition, for both T0 and T1, linear regression models were constructed using migraine reduction as outcome and serum CGRP-LI as independent variable, corrected for age, gender and monthly migraine days (MMD) at baseline.ResultsSerum CGRP-LI did not differ between T0 and T1 (p = 0.30). However, there was an interaction between time and reduction in MMD (p = 0.01). Absolute reduction in MMD in the third month after treatment with erenumab was associated with serum CGRP-LI at T1, 2–4 weeks after starting treatment with erenumab (p = 0.003), but not with serum CGRP-LI at T0 (p = 0.24).ConclusionLower serum CGRP-LI 2–4 weeks after starting treatment with erenumab was associated with a higher reduction in migraine days after three months of treatment. Although the underlying mechanisms remain to be determined, this suggests that changes in CGRP levels, shortly after starting erenumab, are important for its clinical effect.Highlights• Lower serum levels of calcitonin gene-related peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients at 2–4 weeks after starting treatment with erenumab were associated with better treatment response after three months.• Early changes in serum CGRP may be important for the clinical effect of erenumab in migraine. Aim Serum levels of Calcitonin Gene-Related Peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients before and after starting treatment with erenumab were measured to evaluate the association with clinical treatment response. Methods Blood samples were collected from the cubital fossa before (T0) and 2–4 weeks after (T1) starting treatment with erenumab. Clinical response was monitored using a daily headache e-diary. Serum levels of CGRP-LI, assessed using radioimmunoassay, were compared between T0 and T1, correcting for migraine reduction. In addition, for both T0 and T1, linear regression models were constructed using migraine reduction as outcome and serum CGRP-LI as independent variable, corrected for age, gender and monthly migraine days (MMD) at baseline. Results Serum CGRP-LI did not differ between T0 and T1 ( p = 0.30). However, there was an interaction between time and reduction in MMD ( p = 0.01). Absolute reduction in MMD in the third month after treatment with erenumab was associated with serum CGRP-LI at T1, 2–4 weeks after starting treatment with erenumab ( p = 0.003), but not with serum CGRP-LI at T0 ( p = 0.24). Conclusion Lower serum CGRP-LI 2–4 weeks after starting treatment with erenumab was associated with a higher reduction in migraine days after three months of treatment. Although the underlying mechanisms remain to be determined, this suggests that changes in CGRP levels, shortly after starting erenumab, are important for its clinical effect. Highlights • Lower serum levels of calcitonin gene-related peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients at 2–4 weeks after starting treatment with erenumab were associated with better treatment response after three months. • Early changes in serum CGRP may be important for the clinical effect of erenumab in migraine. Highlights • Lower serum levels of calcitonin gene-related peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients at 2–4 weeks after starting treatment with erenumab were associated with better treatment response after three months. • Early changes in serum CGRP may be important for the clinical effect of erenumab in migraine. |
| ArticleNumber | 120 |
| Author | Terwindt, Gisela M. Garrelds, Ingrid M. de Vries Lentsch, Simone Danser, A. H. Jan MaassenVanDenBrink, Antoinette |
| Author_xml | – sequence: 1 givenname: Simone surname: de Vries Lentsch fullname: de Vries Lentsch, Simone organization: Department of Neurology, Leiden University Medical Centre – sequence: 2 givenname: Ingrid M. surname: Garrelds fullname: Garrelds, Ingrid M. organization: Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center – sequence: 3 givenname: A. H. Jan surname: Danser fullname: Danser, A. H. Jan organization: Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center – sequence: 4 givenname: Gisela M. surname: Terwindt fullname: Terwindt, Gisela M. organization: Department of Neurology, Leiden University Medical Centre – sequence: 5 givenname: Antoinette surname: MaassenVanDenBrink fullname: MaassenVanDenBrink, Antoinette email: a.vanharen-maassenvandenbrink@erasmusmc.nl organization: Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center |
| BookMark | eNp9Uctq3TAUFCWlebQ_0JWhm27c6C15UyiXJA0EWvpYC1k-cnWx5VvJvtB8fXXjkJAsstKRzsxozplTdBSnCAi9J_gTIVqeZ4JJw2tMaY0J16y-fYVOCKFNTZlSRw-1bI7Rac5bjClmWrxBx0xi3QitTtDlT0jLWG2ufnyvQqzG0CcbIlQ7OweIc66WHGJfQYK4jLatbK52CfalFfZQzQnsPJbLW_Ta2yHDu_vzDP2-vPi1-VrffLu63ny5qZ0gaq618p7IVnWNaJ3FDoBwor3qSkEF87QhTnHXeGE9d13XKUe9FFY22jHPMDtD16tuN9mt2aUw2vTPTDaYu4cp9camObgBDBGOcUItgNKcCN86x1pBO02xBkxt0fq8au2WdoTOlTGSHZ6IPu3E8Mf00940XHJJaBH4eC-Qpr8L5NmMITsYBhthWrKhijCGJVMH3x-eQbfTkmJZ1QFFpeBK6YKiK8qlKecE_sEMweYQuVkjNyVycxe5uS0k_YzkwlzSmw6mw_Ayla3UXP6JPaRHVy-w_gOtJcJw |
| CitedBy_id | crossref_primary_10_1177_03331024251340066 crossref_primary_10_1186_s10194_024_01769_4 crossref_primary_10_1002_ana_26658 crossref_primary_10_1007_s13760_024_02499_9 crossref_primary_10_3390_pharmaceutics15010293 crossref_primary_10_1007_s11916_023_01154_x crossref_primary_10_1186_s10194_023_01604_2 crossref_primary_10_1186_s10194_024_01758_7 crossref_primary_10_1186_s10194_023_01637_7 crossref_primary_10_3390_ph16070934 crossref_primary_10_1177_03331024241258734 crossref_primary_10_1016_j_bios_2024_116980 crossref_primary_10_2217_pmt_2023_0056 crossref_primary_10_1016_j_pharmthera_2023_108523 |
| Cites_doi | 10.1002/ana.410280213 10.1136/jnnp-2021-327992 10.1016/j.peptides.2019.04.012 10.1016/S0140-6736(19)31946-4 10.1111/ene.15075 10.1177/0333102410368444 10.1002/ana.410330109 10.1001/jama.2018.4853 10.1177/03331024211010306 10.1016/j.maturitas.2020.12.012 10.1177/0333102418779543 10.1111/j.1468-2982.2009.01963.x 10.1016/j.jpain.2009.01.265 10.1002/ejp.1495 10.3390/ijms22073794 10.1186/s10194-021-01336-1 10.1177/0333102418759786 10.3109/00365519009091595 10.1212/WNL.0b013e3182a6cb72 10.1016/S0140-6736(18)32534-0 10.1152/physrev.00034.2013 10.1212/WNL.0000000000010019 10.1016/jmolmet2020101109 10.1186/s10194-020-01193-4 10.1177/0333102418788347 10.1016/S1474-4422(20)30279-9 10.1212/WNL.0000000000012723 10.1177/0333102417738202 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022 The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022. The Author(s). |
| Copyright_xml | – notice: The Author(s) 2022 – notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022. The Author(s). |
| DBID | C6C AAYXX CITATION 3V. 7RV 7TK 7X7 7XB 88E 88G 8AO 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH GNUQQ K9. M0S M1P M2M NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 5PM DOA |
| DOI | 10.1186/s10194-022-01483-z |
| DatabaseName | Springer Nature OA Free Journals CrossRef ProQuest Central (Corporate) Nursing & Allied Health Database Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Local Electronic Collection Information ProQuest Central ProQuest One Community College Coronavirus Research Database ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection PML(ProQuest Medical Library) Psychology Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | CrossRef Publicly Available Content Database ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1129-2377 |
| EndPage | 7 |
| ExternalDocumentID | oai_doaj_org_article_15c3412aee78415fbcc3b52d8208e02a PMC9464612 10_1186_s10194_022_01483_z |
| GrantInformation_xml | – fundername: Nederlandse Organisatie voor Wetenschappelijk Onderzoek grantid: 09150181910040 funderid: http://dx.doi.org/10.13039/501100003246 – fundername: ; grantid: 09150181910040 |
| GroupedDBID | --- -5E -5G -A0 -BR -Y2 -~C .86 0R~ 123 1SB 29K 2P1 2VQ 36B 3V. 4.4 40G 53G 5VS 67Z 6NX 7RV 7X7 88E 8AO 8FI 8FJ 8TC 8UJ AAFWJ AAIAL AAJSJ AAKDD AAKKN AANXM AAWTL AAYZH ABEEZ ABIVO ABMNI ABTEG ABUWG ACACY ACGFS ACOMO ACPRK ACULB ADBBV ADINQ ADKPE ADQRH ADRAZ ADRFC AENEX AFBBN AFGXO AFKRA AFLOW AFPKN AGJBK AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS AZQEC BA0 BAPOH BAWUL BCNDV BENPR BFQNJ BGNMA BKEYQ BMC BPHCQ BVXVI C24 C6C CAG CCPQU COF CS3 CSCUP D-I DIK DL5 DU5 DWQXO EBLON EBS EJD EMB EMOBN EX3 F5P FYUFA GNUQQ GROUPED_DOAJ GXS H13 HF~ HG6 HMCUK HYE HZ~ I09 IHE IXC IXE IZQ I~X KDC KOV KPH KQ8 LAS M1P M2M M48 M4Y M~E NAPCQ NB0 NU0 O9- OAM OK1 PGMZT PIMPY PQQKQ PROAC PSQYO PSYQQ PZZ Q2X RNS ROL RPM RPX RRX RSV S1Z S27 SDH SMD SOJ SV3 T13 TSK U2A UKHRP VC2 WJK WOW Z7U Z82 Z87 ~KM AASML AAYXX ADUKV CITATION 7TK 7XB 8FK COVID K9. PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c517t-87ff16b7d95bca0cee1418f7dee1253f291c74c9f5af4cddd7c2f65a698c3f303 |
| IEDL.DBID | 7X7 |
| ISICitedReferencesCount | 16 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000852876700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1129-2369 1129-2377 |
| IngestDate | Fri Oct 03 12:51:53 EDT 2025 Tue Nov 04 01:52:17 EST 2025 Thu Oct 02 06:21:36 EDT 2025 Sat Oct 18 23:51:21 EDT 2025 Sat Nov 29 04:12:36 EST 2025 Tue Nov 18 22:29:36 EST 2025 Fri Feb 21 02:44:48 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Monoclonal antibodies Serum CGRP Migraine |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c517t-87ff16b7d95bca0cee1418f7dee1253f291c74c9f5af4cddd7c2f65a698c3f303 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/2712654778?pq-origsite=%requestingapplication% |
| PMID | 36089587 |
| PQID | 2712654778 |
| PQPubID | 43392 |
| PageCount | 7 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_15c3412aee78415fbcc3b52d8208e02a pubmedcentral_primary_oai_pubmedcentral_nih_gov_9464612 proquest_miscellaneous_2713306370 proquest_journals_2712654778 crossref_primary_10_1186_s10194_022_01483_z crossref_citationtrail_10_1186_s10194_022_01483_z springer_journals_10_1186_s10194_022_01483_z |
| PublicationCentury | 2000 |
| PublicationDate | 2022-12-01 |
| PublicationDateYYYYMMDD | 2022-12-01 |
| PublicationDate_xml | – month: 12 year: 2022 text: 2022-12-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Milan |
| PublicationPlace_xml | – name: Milan – name: Milano |
| PublicationSubtitle | Official Journal of the "European Headache Federation" and of "Lifting The Burden - The Global Campaign against Headache" |
| PublicationTitle | Journal of headache and pain |
| PublicationTitleAbbrev | J Headache Pain |
| PublicationYear | 2022 |
| Publisher | Springer Milan Springer Nature B.V BMC |
| Publisher_xml | – name: Springer Milan – name: Springer Nature B.V – name: BMC |
| References | van Casteren, Verhagen, van der Arend, van Zwet, MaassenVanDenBrink, Terwindt (CR16) 2021; 97 de Vries Lentsch, Rubio-Beltrán, MaassenVanDenBrink (CR19) 2021; 145 Sonne, Karsdal, Henriksen (CR21) 2021; 46 Tringali, Vollono, Calabresi, Navarra (CR12) 2020; 21 Khodorova, Richter, Vasko, Strichartz (CR23) 2009; 10 de Vries Lentsch, Verhagen, van den Hoek, MaassenVanDenBrink, Terwindt (CR11) 2021; 28 CR14 Ashina, Tepper, Brandes, Reuter, Boudreau, Dolezil (CR28) 2018; 38 Russell, King, Smillie, Kodji, Brain (CR13) 2014; 94 Reuter, Goadsby, Lanteri-Minet, Wen, Hours-Zesiger, Ferrari (CR7) 2018; 392 de Vries Lentsch, Al-Hassany, Ferrari, Terwindt, MaassenVanDenBrink (CR17) 2022 Dodick, Ashina, Brandes, Kudrow, Lanteri-Minet, Osipova (CR5) 2018; 38 Ferrari, Diener, Ning, Galic, Cohen, Yang (CR8) 2019; 394 Hansen, Hauge, Olesen, Ashina (CR4) 2010; 30 MaassenVanDenBrink, Terwindt, Cohen, Barash, Campos, Galic (CR27) 2021; 22 Mulleners, Kim, Láinez, Lanteri-Minet, Pozo-Rosich, Wang (CR9) 2020; 19 Tringali, Navarra (CR20) 2019; 116 Cernuda-Morollón, Larrosa, Ramón, Vega, Martínez-Camblor, Pascual (CR3) 2013; 81 Kruuse, Iversen, Jansen-Olesen, Edvinsson, Olesen (CR26) 2010; 30 Goadsby, Edvinsson, Ekman (CR2) 1990; 28 Skljarevski, Matharu, Millen, Ossipov, Kim, Yang (CR6) 2018; 38 Valdemarsson, Edvinsson, Hedner, Ekman (CR25) 1990; 50 Dux, Babes, Manchen, Sertel-Nakajima, Vogler, Schramm (CR22) 2020; 24 Zheng, Nixdorf-Bergweiler, van Brederode, Alzheimer, Messlinger (CR24) 2021; 22 Goadsby, Edvinsson (CR1) 1993; 33 Goadsby, Reuter, Hallstrom, Broessner, Bonner, Zhang (CR18) 2020; 95 Dodick, Silberstein, Bigal, Yeung, Goadsby, Blankenbiller (CR10) 2018; 319 van Casteren, Verhagen, de Boer, de Vries Lentsch, Fronczek, Van Zwet (CR15) 2021; 41 G Tringali (1483_CR20) 2019; 116 JM Hansen (1483_CR4) 2010; 30 WM Mulleners (1483_CR9) 2020; 19 E Cernuda-Morollón (1483_CR3) 2013; 81 1483_CR14 FA Russell (1483_CR13) 2014; 94 S Valdemarsson (1483_CR25) 1990; 50 G Tringali (1483_CR12) 2020; 21 M Dux (1483_CR22) 2020; 24 PJ Goadsby (1483_CR2) 1990; 28 M Ashina (1483_CR28) 2018; 38 DW Dodick (1483_CR5) 2018; 38 F Zheng (1483_CR24) 2021; 22 A Khodorova (1483_CR23) 2009; 10 DS van Casteren (1483_CR15) 2021; 41 V Skljarevski (1483_CR6) 2018; 38 N Sonne (1483_CR21) 2021; 46 DW Dodick (1483_CR10) 2018; 319 U Reuter (1483_CR7) 2018; 392 A MaassenVanDenBrink (1483_CR27) 2021; 22 S de Vries Lentsch (1483_CR17) 2022 S de Vries Lentsch (1483_CR19) 2021; 145 MD Ferrari (1483_CR8) 2019; 394 DS van Casteren (1483_CR16) 2021; 97 PJ Goadsby (1483_CR18) 2020; 95 PJ Goadsby (1483_CR1) 1993; 33 C Kruuse (1483_CR26) 2010; 30 S de Vries Lentsch (1483_CR11) 2021; 28 |
| References_xml | – volume: 28 start-page: 183 year: 1990 end-page: 187 ident: CR2 article-title: Vasoactive Peptide Release in the Extracerebral Circulation of Humans During Migraine Headache publication-title: Annals of neurology doi: 10.1002/ana.410280213 – year: 2022 ident: CR17 article-title: CGRP-mediated trigeminovascular reactivity in migraine patients treated with erenumab. Journal of neurology, neurosurgery, and psychiatry publication-title: Published Online First: 27 January doi: 10.1136/jnnp-2021-327992 – volume: 116 start-page: 16 year: 2019 end-page: 21 ident: CR20 article-title: Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis publication-title: Peptides doi: 10.1016/j.peptides.2019.04.012 – volume: 394 start-page: 1030 issue: 10203 year: 2019 end-page: 1040 ident: CR8 article-title: Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial publication-title: The Lancet doi: 10.1016/S0140-6736(19)31946-4 – ident: CR14 – volume: 28 start-page: 4194 issue: 12 year: 2021 end-page: 4203 ident: CR11 article-title: Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: A real-life study publication-title: European journal of neurology doi: 10.1111/ene.15075 – volume: 30 start-page: 1179 issue: 10 year: 2010 end-page: 1186 ident: CR4 article-title: Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura publication-title: Cephalalgia doi: 10.1177/0333102410368444 – volume: 33 start-page: 48 year: 1993 end-page: 56 ident: CR1 article-title: Trigeminovascular System and Migraine: studies Characterizing Cerebrovascular and Neuropeptide Changes Seen in Humans and Cat publication-title: Annals of neurology doi: 10.1002/ana.410330109 – volume: 319 start-page: 1999 issue: 19 year: 2018 end-page: 2008 ident: CR10 article-title: Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial publication-title: JAMA doi: 10.1001/jama.2018.4853 – volume: 41 start-page: 1161 issue: 11–12 year: 2021 end-page: 1171 ident: CR15 article-title: E-diary use in clinical headache practice: A prospective observational study publication-title: Cephalalgia doi: 10.1177/03331024211010306 – volume: 145 start-page: 73 year: 2021 end-page: 77 ident: CR19 article-title: Changing levels of sex hormones and calcitonin gene-related peptide (CGRP) during a woman’s life: Implications for the efficacy and safety of novel antimigraine medications publication-title: Maturitas doi: 10.1016/j.maturitas.2020.12.012 – volume: 38 start-page: 1442 issue: 8 year: 2018 end-page: 1454 ident: CR6 article-title: Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial publication-title: Cephalalgia doi: 10.1177/0333102418779543 – volume: 30 start-page: 467 issue: 4 year: 2010 end-page: 474 ident: CR26 article-title: Calcitonin gene-related peptide (CGRP) levels during glyceryl trinitrate (GTN)-induced headache in healthy volunteers publication-title: Cephalalgia doi: 10.1111/j.1468-2982.2009.01963.x – volume: 10 start-page: 740 issue: 7 year: 2009 end-page: 749 ident: CR23 article-title: Early and late contributions of glutamate and CGRP to mechanical sensitization by endothelin-1 publication-title: The journal of pain: official journal of the American Pain Society doi: 10.1016/j.jpain.2009.01.265 – volume: 24 start-page: 383 issue: 2 year: 2020 end-page: 397 ident: CR22 article-title: High-dose phenylephrine increases meningeal blood flow through TRPV1 receptor activation and release of calcitonin gene-related peptide publication-title: European journal of pain (London, England) doi: 10.1002/ejp.1495 – volume: 22 start-page: 3794 issue: 7 year: 2021 ident: CR24 article-title: Excitatory Effects of Calcitonin Gene-Related Peptide (CGRP) on Superficial Sp5C Neurons in Mouse Medullary Slices publication-title: International journal of molecular sciences doi: 10.3390/ijms22073794 – volume: 22 start-page: 152 issue: 1 year: 2021 ident: CR27 article-title: Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study publication-title: The journal of headache and pain doi: 10.1186/s10194-021-01336-1 – volume: 38 start-page: 1026 issue: 6 year: 2018 end-page: 1037 ident: CR5 article-title: ARISE: A Phase 3 randomized trial of erenumab for episodic migraine publication-title: Cephalalgia doi: 10.1177/0333102418759786 – volume: 50 start-page: 385 issue: 4 year: 1990 end-page: 388 ident: CR25 article-title: Hormonal influence on calcitonin gene-related peptide in man: effects of sex difference and contraceptive pills publication-title: Scandinavian journal of clinical and laboratory investigation doi: 10.3109/00365519009091595 – volume: 97 start-page: e1661-e1671 issue: 17 year: 2021 ident: CR16 article-title: Comparing Perimenstrual and Nonperimenstrual Migraine Attacks Using an e-Diary publication-title: Neurology – volume: 81 start-page: 1191 year: 2013 end-page: 1196 ident: CR3 article-title: Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine publication-title: Neurology doi: 10.1212/WNL.0b013e3182a6cb72 – volume: 392 start-page: 2280 issue: 10161 year: 2018 end-page: 2287 ident: CR7 article-title: Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study publication-title: The Lancet doi: 10.1016/S0140-6736(18)32534-0 – volume: 94 start-page: 1099 issue: 4 year: 2014 end-page: 1142 ident: CR13 article-title: Calcitonin gene-related peptide: physiology and pathophysiology publication-title: Physiological reviews doi: 10.1152/physrev.00034.2013 – volume: 95 start-page: e469-e479 issue: 5 year: 2020 ident: CR18 article-title: One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study publication-title: Neurology doi: 10.1212/WNL.0000000000010019 – volume: 46 start-page: 101109 year: 2021 ident: CR21 article-title: Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases publication-title: Mol Metab doi: 10.1016/jmolmet2020101109 – volume: 21 start-page: 124 issue: 1 year: 2020 ident: CR12 article-title: A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB publication-title: The journal of headache and pain doi: 10.1186/s10194-020-01193-4 – volume: 38 start-page: 1611 issue: 10 year: 2018 end-page: 1621 ident: CR28 article-title: Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study publication-title: Cephalalgia doi: 10.1177/0333102418788347 – volume: 19 start-page: 814 issue: 10 year: 2020 end-page: 825 ident: CR9 article-title: Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial publication-title: The Lancet Neurology doi: 10.1016/S1474-4422(20)30279-9 – volume: 145 start-page: 73 year: 2021 ident: 1483_CR19 publication-title: Maturitas doi: 10.1016/j.maturitas.2020.12.012 – volume: 116 start-page: 16 year: 2019 ident: 1483_CR20 publication-title: Peptides doi: 10.1016/j.peptides.2019.04.012 – volume: 28 start-page: 183 year: 1990 ident: 1483_CR2 publication-title: Annals of neurology doi: 10.1002/ana.410280213 – volume: 319 start-page: 1999 issue: 19 year: 2018 ident: 1483_CR10 publication-title: JAMA doi: 10.1001/jama.2018.4853 – volume: 41 start-page: 1161 issue: 11–12 year: 2021 ident: 1483_CR15 publication-title: Cephalalgia doi: 10.1177/03331024211010306 – volume: 97 start-page: e1661-e1671 issue: 17 year: 2021 ident: 1483_CR16 publication-title: Neurology doi: 10.1212/WNL.0000000000012723 – volume: 38 start-page: 1611 issue: 10 year: 2018 ident: 1483_CR28 publication-title: Cephalalgia doi: 10.1177/0333102418788347 – volume: 19 start-page: 814 issue: 10 year: 2020 ident: 1483_CR9 publication-title: The Lancet Neurology doi: 10.1016/S1474-4422(20)30279-9 – volume: 28 start-page: 4194 issue: 12 year: 2021 ident: 1483_CR11 publication-title: European journal of neurology doi: 10.1111/ene.15075 – volume: 38 start-page: 1442 issue: 8 year: 2018 ident: 1483_CR6 publication-title: Cephalalgia doi: 10.1177/0333102418779543 – volume: 50 start-page: 385 issue: 4 year: 1990 ident: 1483_CR25 publication-title: Scandinavian journal of clinical and laboratory investigation doi: 10.3109/00365519009091595 – volume: 22 start-page: 152 issue: 1 year: 2021 ident: 1483_CR27 publication-title: The journal of headache and pain doi: 10.1186/s10194-021-01336-1 – volume: 10 start-page: 740 issue: 7 year: 2009 ident: 1483_CR23 publication-title: The journal of pain: official journal of the American Pain Society doi: 10.1016/j.jpain.2009.01.265 – volume: 46 start-page: 101109 year: 2021 ident: 1483_CR21 publication-title: Mol Metab doi: 10.1016/jmolmet2020101109 – volume: 30 start-page: 467 issue: 4 year: 2010 ident: 1483_CR26 publication-title: Cephalalgia doi: 10.1111/j.1468-2982.2009.01963.x – volume: 392 start-page: 2280 issue: 10161 year: 2018 ident: 1483_CR7 publication-title: The Lancet doi: 10.1016/S0140-6736(18)32534-0 – volume: 22 start-page: 3794 issue: 7 year: 2021 ident: 1483_CR24 publication-title: International journal of molecular sciences doi: 10.3390/ijms22073794 – volume: 81 start-page: 1191 year: 2013 ident: 1483_CR3 publication-title: Neurology doi: 10.1212/WNL.0b013e3182a6cb72 – volume: 30 start-page: 1179 issue: 10 year: 2010 ident: 1483_CR4 publication-title: Cephalalgia doi: 10.1177/0333102410368444 – year: 2022 ident: 1483_CR17 publication-title: Published Online First: 27 January doi: 10.1136/jnnp-2021-327992 – ident: 1483_CR14 doi: 10.1177/0333102417738202 – volume: 94 start-page: 1099 issue: 4 year: 2014 ident: 1483_CR13 publication-title: Physiological reviews doi: 10.1152/physrev.00034.2013 – volume: 95 start-page: e469-e479 issue: 5 year: 2020 ident: 1483_CR18 publication-title: Neurology doi: 10.1212/WNL.0000000000010019 – volume: 33 start-page: 48 year: 1993 ident: 1483_CR1 publication-title: Annals of neurology doi: 10.1002/ana.410330109 – volume: 38 start-page: 1026 issue: 6 year: 2018 ident: 1483_CR5 publication-title: Cephalalgia doi: 10.1177/0333102418759786 – volume: 24 start-page: 383 issue: 2 year: 2020 ident: 1483_CR22 publication-title: European journal of pain (London, England) doi: 10.1002/ejp.1495 – volume: 394 start-page: 1030 issue: 10203 year: 2019 ident: 1483_CR8 publication-title: The Lancet doi: 10.1016/S0140-6736(19)31946-4 – volume: 21 start-page: 124 issue: 1 year: 2020 ident: 1483_CR12 publication-title: The journal of headache and pain doi: 10.1186/s10194-020-01193-4 |
| SSID | ssj0020385 |
| Score | 2.3900664 |
| Snippet | Aim
Serum levels of Calcitonin Gene-Related Peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients before and after starting treatment with... AimSerum levels of Calcitonin Gene-Related Peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients before and after starting treatment with... Serum levels of Calcitonin Gene-Related Peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients before and after starting treatment with erenumab... • Lower serum levels of calcitonin gene-related peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients at 2–4 weeks after starting treatment with... Highlights • Lower serum levels of calcitonin gene-related peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients at 2–4 weeks after starting... |
| SourceID | doaj pubmedcentral proquest crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 120 |
| SubjectTerms | Calcitonin Calcitonin gene-related peptide CGRP Headache Immunoreactivity Internal Medicine Medicine Medicine & Public Health Migraine Monoclonal antibodies Neurology Pain Medicine Patients Peptides Radioimmunoassay Regression analysis Serum Serum levels |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Nb9UwDLfQhBAXxKcoDBQkblDRpPk8wsSDA0wTArRblKbJeNJeN-29t8P-euI0fdBJwIVb1aZtYjuxLds_A7wMUvuoNFb-ClYjIHmtRXA1j43spBfe5Dru75_U4aE-PjZHv7X6wpywER54JNwbKnw6aJkLASNkInbet51gfdJcOjQsm0aNMpMzVVwtjHfltirM1KyVZiqX0RKL5ijC4TJMSeC6ra9mKikj98_MzevJktciplkRLe7CnWJBkrfjzO_BjTDch1ufS4z8ASzS9t-uyMGHL0dkOZDV8gS7QARSEFTXBFPdTwiW-W1XriNuTc4LjtNlILvE84fwbfH-68HHunRLqL2gapOOtRip7FRvROddk5Qf5VRH1acLJtrIDPWKexOFi9z3fa88i1I4abRvY9Jkj2BvOBvCYyBdm-yQwL30uuVd-qiTFDnquEOELFUBnQhmfYESx44Wpza7FFrakcg2EdlmIturCl7t3jkfgTT-Ovod8mE3EkGw840kGraIhv2XaFSwP3HRlp25tkxRhg2Xla7gxe5x2lMYKHFDONvmMW1ypVrVVKBm3J9NaP5kWP7I6NyGS57MxgpeT3Ly6-d_XvCT_7Hgp3CboVznbJt92NtcbMMzuOkvN8v1xfO8Q34COGESNA priority: 102 providerName: Directory of Open Access Journals – databaseName: SpringerLink Open Access Journals dbid: C24 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdgIMQL34iMgYzEG0Sqv-1HqCg8wDQhQHuzHMfuKtF0ato97K-fz3WKMgESvEXJxXHOd76z7u53CL0OUvuoNFT-CloDIHmtRXA1jxPZSC-8yXXcPz6r42N9empOSlFYP2S7DyHJvFNntdYSit0IwNhSSCXgmtWXN9EtQbSBRL4p1DiUYxbEunJLFWpqyqQZSmV-O8bIHGXU_pGreT1R8lq0NBuh2f3_m_4DdK84nfjdTkoeohuhe4TufClh9cdolnaM7RJPP349wYsOLxdzaBwRcAFd7TFkx88xVAZul67BrsfnBfrpIuB9rvoT9H324dv0U10aLNReELVJO2GMRDaqNaLxbpLsJeFER9WmCypYpIZ4xb2JwkXu27ZVnkYpnDTas5iM31N00K268AzhhiXXJXAvvWa8SYM6SUAIHHcAqqUqRAY-W1_Qx6EJxk-bTyFa2h2DbGKQzQyylxV6s3_nfIe98Vfq97B8e0rAzc43Vuu5LWpoifDJbFMXAsRbRWy8Z42gbfKDdJhQV6GjYfFtUebeUkUo9GhWukKv9o-TGkJsxXVhtc00LJ2-mJpUSI2EZjSh8ZNucZYBvQ2XPHmaFXo7iM6vj__5hw__jfw5uktB-nIqzhE62Ky34QW67S82i379MqvQFS3IFoo priority: 102 providerName: Springer Nature |
| Title | Serum CGRP in migraine patients using erenumab as preventive treatment |
| URI | https://link.springer.com/article/10.1186/s10194-022-01483-z https://www.proquest.com/docview/2712654778 https://www.proquest.com/docview/2713306370 https://pubmed.ncbi.nlm.nih.gov/PMC9464612 https://doaj.org/article/15c3412aee78415fbcc3b52d8208e02a |
| Volume | 23 |
| WOSCitedRecordID | wos000852876700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1129-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0020385 issn: 1129-2369 databaseCode: DOA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVAVX databaseName: SpringerLink Open Access Journals customDbUrl: eissn: 1129-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0020385 issn: 1129-2369 databaseCode: C24 dateStart: 20000701 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdgQ4iX8TkRGJWReIOIxvFXnhCrVkCiVVTBVJ4ix7FLJZqWpt3D_vr5XKdVJrEXXqIkdj7vznf23f0OoXeGS22FhMxfRmIAJI8lMyqmts9LrpnOfB735XcxHsvpNMvDglsTwirbMdEP1NVSwxr5RyISAoVyhfy0-htD1SjwroYSGvfRMZTNBj4X08OEC7xevrgKyWKS8qxNmpEcUucSAMUlEJhAZRpfdxSTx-_vGJ23QyZv-U29Oho-_t8PeYJOgiGKP-845ym6Z-pn6OEouNqfo6EbRbYLPPgyyfG8xov5DIpJGByAWBsMEfMzDNmC24UqsWrwKsBBXRm8j19_gX4OL34Mvsah6EKsWSI2bnS0NuGlqDJWatV3OjShibSicjuEpZZkiRZUZ5YpS3VVVUITy5nimdSpdQrxFB3Vy9q8RLhMnTljqOZaprR0N1U8AcZQVAHQlohQ0v7xQgdEciiM8afwMxPJix2VCkelwlOpuI7Q-_01qx0ex529z4GQ-56Ape1PLNezIohmkTDtVDlRxoAPltlS67RkpHK2kTR9oiJ01hKyCALeFAcqRujtvtmJJvhbVG2WW98ndTOyVPQjJDrs03mhbks9_-1BvjPKqbM-I_ShZbTDw__9wa_uftfX6BEBlvfhOGfoaLPemjfogb7azJt1zwnP5LLnRchvZQ8dn1-M84k7GhDa8-sVbjsiI9eSfxvlv24A8gooNA |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwED-NDgEvfCMCA4wETxDROP7KA0IwKKvWVhUaaDwZx7FLJZqWtR1ifxR_I7406dRJ7G0PvEWx49jxz-dz7u53AM-cUNZLhZG_nMZISB4r7kzMfFvkwnKbVXHcX3pyMFCHh9lwC_40sTDoVtnIxEpQF1OL_8hfUZlQTJQr1ZvZzxizRqF1tUmhsYLFvvv9KxzZ5q-778P8Pqe08-Fgdy-uswrElidyEZa_94nIZZHx3Jp22CQSligvi3BBeepplljJbOa58cwWRSEt9YIbkSmb-iDxQ7uXYJsh2FuwPez2h1_XRzy0s1XpXGgW01RkTZiOEhislyANL0VXCKbS-GRjK6wyBmyouWedNM9YaqsNsHPjf_t0N-F6rWqTt6u1cQu2XHkbrvRrZ4I70Alycjkhux8_Dcm4JJPxCNNlOFJTzc4JxgSMCMZDLicmJ2ZOZjXh1bEjaw_9u_D5QkZxD1rltHT3geRpUNgcs8KqlOWhUSMShL5hBqnEZARJM8Pa1pzrmPrjh67OXkroFSp0QIWuUKFPInixfma2Yhw5t_Y7BM66JrKFVzemRyNdCx-dcBuUFWqcQysz97m1ac5pEbQ_5drURLDTAEfXImyuT1ETwdN1cRA-aFEypZsuqzppOHOmsh2B3IDrRoc2S8rx94rGPGOCBf06gpcNsE9f_u8BPzi_r0_g6t5Bv6d73cH-Q7hGcblVzkc70FocLd0juGyPF-P50eN66RL4dtGQ_wsVfIGU |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwED-NDk174RsRGGAkeIJojeOvPCAEG4VqW1UhQOMpOI7dVaJp6ccQ-9P46_C5SadOYm974C2KHceOfz6fc3e_A3huhTJOKoz85TRGQvJYcatj5tqiEIabLMRxfz2UvZ46Ps76G_CniYVBt8pGJgZBXY4N_iPfpTKhmChXql1Xu0X09ztvJj9jzCCFltYmncYSIgf29y9_fJu97u77uX5Baef9572PcZ1hIDY8kXMvCpxLRCHLjBdGt_2GkbBEOVn6C8pTR7PESGYyx7VjpixLaagTXItMmdR56e_bvQabXiVntAWb_e5R_9vquIc2t5DahWYxTUXWhOwogYF7CVLyUnSLYCqNz9a2xZA9YE3lveiwecFqGzbDzs3_-TPeghu1Ck7eLtfMbdiw1R3YOqqdDO5Cx8vPxYjsffjUJ8OKjIYDTKNhSU1BOyMYKzAgGCe5GOmC6BmZ1ERYp5asPPfvwZcrGcV9aFXjyj4AUqRekbPMCKNSVvhGtUhwSWimkWJMRpA0s52bmosdU4L8yMOZTIl8iZDcIyQPCMnPIni5emayZCK5tPY7BNGqJrKIhxvj6SCvhVKecOOVGKqtReszd4UxacFp6bVCZdtUR7DTgCivRdssP0dQBM9WxV4ooaVJV3a8CHVSfxZNZTsCuQbdtQ6tl1TDk0BvnjHBvN4dwasG5Ocv__eAH17e16ew5XGeH3Z7B49gm-LKCz5JO9CaTxf2MVw3p_PhbPqkXsUEvl814v8Cv86KVA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+CGRP+in+migraine+patients+using+erenumab+as+preventive+treatment&rft.jtitle=Journal+of+headache+and+pain&rft.au=de+Vries+Lentsch%2C+Simone&rft.au=Garrelds%2C+Ingrid+M&rft.au=Danser%2C+A+H+Jan&rft.au=Terwindt%2C+Gisela+M&rft.date=2022-12-01&rft.issn=1129-2377&rft.eissn=1129-2377&rft.volume=23&rft.issue=1&rft.spage=120&rft_id=info:doi/10.1186%2Fs10194-022-01483-z&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1129-2369&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1129-2369&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1129-2369&client=summon |